Abdul dissects the FDA’s disastrous decision to approve the new Alzheimer’s drug aducanumab despite the evidence that it fails to improve symptoms—and its aftermath and implications for the future of Big Pharma. He speaks with Professor Aaron Kesselheim, a prescription drug policy expert and a former member of the FDA Advisory Panel, who resigned at the FDA ignored the panel’s overwhelming opposition to approve it the drug.
Take Crooked's listener survey: crooked.com/survey
For a transcript of this episode, please visit crooked.com/americadissected.
Learn more about your ad choices. Visit podcastchoices.com/adchoices